What is GANX's dilution risk score?

GANX has a latest available DilutionScore record of 52/100, categorized as high dilution risk by the DilutionWatch scoring model. DilutionWatch displays SEC filing and dilution indicators for GANX, including shelf registrations, ATM offerings, warrant exercises, PIPE deals, and reverse split signals when detected in source data.

What SEC filings does DilutionWatch track for GANX?

DilutionWatch tracks 25 SEC filing types for GANX including S-3 shelf registrations, 424B prospectuses (ATM offerings), S-1 registration statements, 8-K material events, warrant exercise notices, convertible note agreements, and Form 4 insider transactions. Alerts are delivered via email within minutes of a filing appearing on EDGAR.

How does stock dilution affect GANX shareholders?

Stock dilution occurs when a company issues new shares, reducing the ownership percentage of existing shareholders. For GANX, common dilution events include at-the-market (ATM) stock offerings, shelf registration drawdowns, warrant exercises, and convertible note conversions. Each event increases the share count and can pressure the stock price lower.

Is DilutionWatch free for GANX tracking?

DilutionWatch provides a free tier that shows DilutionScores and basic filing history for GANX. Premium plans ($19.95/month Basic, $39.95/month Premium) unlock real-time email alerts, the full Pulse™ feed, advanced dilution forecasts, and access to all 10,000+ tracked tickers.

GANX Dilution Risk Score: 52/100 (HIGH)

Score Breakdown

📋 Offering Ability

60

💰 Cash Runway

65

📊 Float Risk

10

⚠️ Warrant Exposure

15

🔄 Convertible Debt

40

Dilution Forecast

🌥️

Advisory

Moderate dilution signals present

model est. 24%

🔄 Reverse Split model est. 40%

• 50-day avg $1.88 approaching $1 threshold

• 11 months cash with weak price

💰 Capital Raise model 15%

• Under 12 months cash (11mo)

🔔 Track GANX — Get forecast alerts →

Market Data

Market Cap$83.18M

Shares Outstanding43.64M

Float41.65M

Cash$15.10M

Debt$343.7K

Short InterestN/A

Institutional Holdings

QoQ: ↑ 10.6% shares (2026Q1 vs prior)

43 institutional holders · 9.05M shares

#1 MARSHALL WACE, LLP 1.77M shares

#2 Potomac Capital Management, Inc. 1.01M shares

#3 VANGUARD CAPITAL MANAGEMENT LLC 799.8K shares

+ 17 more holders Sign up free to view →

Institutional holder totals are aggregated from ownership filings and may use a different share basis or reporting date than public float. They are not a reconciliation against tradeable float.

Short Interest

Short Interest3.21M

Days to Cover6.7

% of Float7.7%

FINRA data as of Jul 31, 2026

Insider Buy/Sell Ratio

Recent SEC Activity

xbrl XBRL WARRANT 2025-12-31

Full SEC filing analysis available with free account →

Recent News

No recent news

Factual GANX Dilution Snapshot

Gain Therapeutics, Inc. (GANX) has a DilutionScore of 52/100, rated High dilution risk. Score date: August 28, 2026.

Stored outstanding warrants: 200,000.
Recent SEC activity tracked for GANX: xbrl on 2025-12-31.

This automatically generated snapshot is assembled from stored DilutionWatch data fields and may contain data-source errors or omissions. It is not financial advice, not investment research, and not a recommendation. Do your own research and review the full disclaimer and terms of service.